Navigation Links
Response Biomedical Corporation Reports 2008 Financial Results
Date:3/30/2009

own and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our limited available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; current financial market conditions which may negatively affect our ability to obtain financing; our ability to meet the continued listing requirements of the TSX under its ongoing delisting review; changing facility costs and other risks relating to our facilities expansion plans; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our a
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Tray-Pak Direct Mailer Garners 21% Response, Design Award
2. 2-day results predict ultimate response to therapy in chronic hepatitis C
3. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
4. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
5. New Study Shows Probiotic Strain Effective in Boosting Immune Response
6. Cell pathway on overdrive prevents cancer response to dietary restriction
7. Response Biomedical Named Medical Device Company of the Year by LifeSciences British Columbia
8. AdvaMed Response to the Medical Device Safety Act
9. Ethnicity May Drive Response to Obesity, Insulin Resistance
10. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
11. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... about multiple births dominating the media, it is easy to ... many couples trying to start a family. In fact, more ... number is growing. In the past 10 years the ... billion. Despite the troubled economy, reproductive medicine is thriving, ...
... Researchers from Thomas Jefferson University have identified a ... the growth and migration of prostate cancer cells, especially ... the American Journal of Pathology . , They ... the protein when compared to normal prostate cells, according ...
... socioeconomic characteristics of people who play state lotteries are similar ... with a small potential for high return, and just like ... invest this way in the stock market, research from The ... "Who Gambles in the Stock Market?" Alok Kumar, assistant professor ...
... Zuckerman, M.D., first considered a life in medicine at the ... weekly trials and tribulations of a young television doctor named ... show, it sparked an idea which led to an impressive ... Today, Dr. Zuckerman was named President of the American ...
... Healthcare Management Systems, Inc. (R) (HMS) ... Act of 2009 (ARRA) as it unfolds, ... the HIMSS informational webinar yesterday on ARRA, even with ... to wait to implement electronic health record (EHR) technology ...
... Consecutive Profitable Quarter Earns $.08 Per Diluted ShareLARGO, ... Bulletin Board: UVICF ; TSX Venture Exchange: ... specialty contact lenses, today reported its operating results ... (FY2009).Net sales, excluding royalty income, increased 1.2% to ...
Cached Medicine News:Health News:A Recession-Resistant Business? Introducing FertilityAuthority.com 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Investors who 'gamble' in the stock market have same characteristics as lottery players 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 3Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 3Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 4Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 5
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ... systems especially for type 1 diabetes patients. ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014 /PRNewswire/ ... addressing the unmet needs of severely obese patients, ... study of beloranib, a selective inhibitor of methionine ... (PWS), a severe form of genetic obesity.  These ... and body composition, including reductions in body fat ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The ... offers Los Angeles a premier and ... laser and a $99 treatment special. Dr. Brandeis, focus is ... technology and offering expert medical advice to all patients. ... dramatic increase in the presence of tattoo regret and patients ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... JERUSALEM, Israel, June 15 ,The University of Pittsburgh ... announced today that the Institute has joined an elite,group of ... are now,enrolling patients to participate in the ExCell research study. ... assessing the safety and efficacy of StemEx(R), an,investigational product derived ...
... , IRVINE, Calif., June 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that ... utility of Masimo PVI as a noninvasive and continuous ... this week at the European Society of Anaesthesiology (ESA) ...
Cached Medicine Technology:UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 2UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products: